{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:35:46Z","timestamp":1791304546803,"version":"4.3.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immunoglobulin light chain (AL) amyloidosis may be caused by a B-cell non-Hodgkin lymphoma (NHL) rather than a plasma cell neoplasm in rare cases, which presents unique diagnostic and management considerations. NHL associated with AL will often have an IgM paraprotein; thus, this disease is termed IgM-related AL amyloidosis (IgM AL). The clinical presentation of IgM AL is more likely to involve the lungs, peripheral nerves, and soft tissue; cardiac involvement is less common. Patients with IgM AL amyloidosis should undergo a lymphoma-directed work-up including evaluation for nodal and extranodal disease. Additionally, patients with an IgM paraproteinemia should be screened for AL amyloidosis through history and physical examination. Treatment regimens active against underlying lymphoma, rather than plasma cell-directed regimens, are recommended. Historical response rates in IgM AL have been poor; prospective studies of novel antineoplastic regimens may improve treatment outcomes.<\/jats:p>","DOI":"10.3389\/fonc.2022.915420","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T06:48:56Z","timestamp":1671086936000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Diagnosis and management of AL amyloidosis due to B-cell non-Hodgkin lymphoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Callie","family":"Berkowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dittus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.3123","article-title":"European Collaborative study defining clinical profile outcomes and novel prognostic criteria in monoclonal immunoglobulin m\u2013related light chain amyloidosis","volume":"34","author":"Sachchithanantham","year":"2016","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2016.08.013","article-title":"Monoclonal IgM-related AL amyloidosis","volume":"29","author":"Milani","year":"2016","journal-title":"Best Pract Res Clin Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002762","article-title":"Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis","volume":"135","author":"Basset","year":"2020","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1309\/AJCPI08WAKYVLHHA","article-title":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with amyloid deposition: a clinicopathologic case series","volume":"137","author":"Ryan","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-453001","article-title":"Systemic light chain amyloidosis: an update for treating physicians","volume":"121","author":"Merlini","year":"2013","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0667-6","article-title":"IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features","volume":"34","author":"Sidana","year":"2020","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0286-7","article-title":"Primary systemic amyloidosis in patients with waldenstr\u00f6m macroglobulinemia","volume":"33","author":"Zanwar","year":"2019","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26155","article-title":"The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance","volume":"96","author":"Castillo","year":"2021","journal-title":"Am J Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/bjh.14196","article-title":"Recommendations for the diagnosis and initial evaluation of patients with waldenstr\u00f6m macroglobulinaemia: A task force from the 8th international workshop on waldenstr\u00f6m macroglobulinaemia","volume":"175","author":"Castillo","year":"2016","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.08.016","article-title":"Systemic amyloidosis due to low-grade lymphoma","volume":"34","author":"Wechalekar","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2015.1092433","article-title":"Clinical presentation and treatment responses in IgM-related AL amyloidosis","volume":"22","author":"Sissoko","year":"2015","journal-title":"Amyloid"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1182384","DOI":"10.1155\/2022\/1182384","article-title":"Utility of bruton's tyrosine kinase inhibitors in light chain amyloidosis caused by lymphoplasmacytic lymphoma (Waldenstr\u00f6m's macroglobulinemia)","volume":"2022","author":"Bou Zerdan","year":"2022","journal-title":"Adv Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003087","article-title":"Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated waldenstr\u00f6m macroglobulinemia","volume":"4","author":"Castillo","year":"2020","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-846493","article-title":"Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine","volume":"132","author":"Manwani","year":"2018","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2011.n.033","article-title":"Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone","volume":"11","author":"Palladini","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: The ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.003","article-title":"Autologous stem cell transplant for IgM-associated amyloid light-chain amyloidosis","volume":"25","author":"Sidiqi","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.915420\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T06:48:58Z","timestamp":1671086938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.915420\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":17,"alternative-id":["10.3389\/fonc.2022.915420"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.915420","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]},"article-number":"915420"}}